Takeda announces approval of Nuvaxovid Covid-19 vaccine in Japan
Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
This could be a game-changer for the prevention of the disease; seeing more doses of the life-saving jab reach more girls
Collaboration awarded €3 million grant by the Bill & Melinda Gates Foundation
Under the agreement, Technology Development Board and Bharat Biotech have pledged the support of Rs.200 crore each to create a continuous corpus of Rs.400 crores for the project
U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current USFDA approved or emergency use authorized-vaccines
It is the fourth vaccine to get the nod for 12 years and older after Biological E’s Corbevax, Bharat Biotech’s Covaxin and Zydus Lifesciences Zy-CoV-D
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
The announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for children aged 6-11 years
Intranasal immunization lowers the viral load below the limit of detection in lungs of hamsters
Subscribe To Our Newsletter & Stay Updated